/Companies

Ilico Genetics

Santiago, CL · Founded 2020 · 5 employees on LinkedIn · 2 known investors

Find your way into Ilico Genetics

Each arrow is one introduction. Sign up to fill in the first one.

488 people can intro you to Fernando

Ask Mario Mora to introduce you to Fernando Alarcon

You →Mario · together at Entel →Fernando

140 people can intro you to Alejandro

Ask Jamie Chen to introduce you to Alejandro Corvalán

You →Jamie · together at MD Anderson Cancer Center →Alejandro

Sign up to find every way you can get introduced to Ilico Genetics

  • Your email: who you already know at Ilico Genetics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Ilico Genetics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Ilico Genetics develops a blood-based molecular test for the early detection of gastric cancer using methylated DNA markers, designed to identify disease years before traditional methods. The company serves gastroenterologists and patients in the oncology diagnostics space, with a platform technology applicable to precision medicine and disease prevention.

Founders & leadership

Ilico Genetics was founded in 2020 by Alejandro Corvalán.

ACAlejandro Corvalán
Alejandro CorvalánMDMD with degrees from Universidad de Chile and ECFMG certification; previously worked as a pathologist at Mount Sinai School of Medicine and postdoctoral fellow in molecular pathology at Tokyo Medical and Dental School and Kagoshima University. Currently Full Professor and Principal Investigator at the Advanced Center for Chronic Diseases at Pontificia Universidad Católica de Chile, conducting translational research on gastric cancer molecular biology.
FAFernando Alarcon
Fernando AlarconMBAFernando Alarcon has a background in corporate finance and M&A advisory across Latin America, working on valuations, capital raises, and growth strategy in healthcare and pharma sectors. He is co-founder of Ilico Genetics, which develops a blood-based molecular test using methylated DNA markers to detect gastric cancer early in high-risk patients.
MJ
Maria Jose Maturana RojasNamed on SEC filing
AH
Alejandro Hernan Corvalan RodriguezNamed on SEC filing
FA
Fernando A Alarcon HardyNamed on SEC filing
MJMaria J. Maturana
Maria J. MaturanaMSc

Investors · 2

Also in the syndicate · 1

Life Science Greenhouse Investments

Funding

SEC filings, press & company announcements

$457.7K disclosed across 1 of 2 rounds · 2023

  • Undisclosed amountSAFE roundSep 2023

    Life Science Greenhouse Investments

    Source ↗
▶$457.7KraisedOct 2023 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Maria Jose Maturana RojasDirector
  • Alejandro Hernan Corvalan RodriguezDirector
  • Fernando A Alarcon HardyExecutive Officer, Director
Amount sold
$457.7K
Proceeds to insiders
$75K
First sale
Jan 2023
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Ilico Genetics do?
Ilico Genetics develops a blood-based molecular test for the early detection of gastric cancer using methylated DNA markers, designed to identify disease years before traditional methods. The company serves gastroenterologists and patients in the oncology diagnostics space, with a platform technology applicable to precision medicine and disease prevention.
Who founded Ilico Genetics?
Ilico Genetics was founded by Alejandro Corvalán in 2020.
Who are Ilico Genetics's investors?
Ilico Genetics's investors include Life Sciences Greenhouse Investments.
How much funding has Ilico Genetics raised?
Ilico Genetics has disclosed $457.7K raised across 1 of its 2 known rounds.
Where is Ilico Genetics headquartered?
Ilico Genetics is headquartered in Santiago, CL.